Abstract
Background: A common missense variant of the CDKN2A gene (A148T) predisposes to malignant melanoma in Poland. An association between malignant melanoma and breast cancer has been reported in several families with CDKN2A mutations,
Objective: To determine whether this variant also predisposes to breast cancer.
Methods: Genotyping was undertaken in 4209 cases of breast cancer, unselected for family history, from 18 hospitals throughout Poland and in 3000 controls.
Results: The odds ratio (OR) associated with the CDKN2A allele for women diagnosed with breast cancer before the age of 50 was 1.5 (p = 0.002) and after age 50 it was 1.3 (p = 0.2). The effect was particularly strong for patients diagnosed at or before the age of 30 (OR = 3.8; p = 0.0002).
Conclusions: CDKN2A appears to be a low penetrance breast cancer susceptibility gene in Poland. The association should be confirmed in other populations.
Full Text
The Full Text of this article is available as a PDF (62.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aitken J., Welch J., Duffy D., Milligan A., Green A., Martin N., Hayward N. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst. 1999 Mar 3;91(5):446–452. doi: 10.1093/jnci/91.5.446. [DOI] [PubMed] [Google Scholar]
- Belinsky S. A., Nikula K. J., Palmisano W. A., Michels R., Saccomanno G., Gabrielson E., Baylin S. B., Herman J. G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891–11896. doi: 10.1073/pnas.95.20.11891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bertram Chandra G., Gaut Rupert M., Barrett Jennifer H., Pinney Elizabeth, Whitaker Linda, Turner Faye, Bataille Veronique, Dos Santos Silva Isabel, J Swerdlow Anthony, Bishop D. Timothy. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol. 2002 Oct;119(4):961–965. doi: 10.1046/j.1523-1747.2002.01825.x. [DOI] [PubMed] [Google Scholar]
- Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Måsbäck A., Westerdahl J., Olsson H., Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000 Aug 2;92(15):1260–1266. doi: 10.1093/jnci/92.15.1260. [DOI] [PubMed] [Google Scholar]
- Burri N., Shaw P., Bouzourene H., Sordat I., Sordat B., Gillet M., Schorderet D., Bosman F. T., Chaubert P. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab Invest. 2001 Feb;81(2):217–229. doi: 10.1038/labinvest.3780230. [DOI] [PubMed] [Google Scholar]
- Cybulski C., Górski B., Huzarski T., Masojć B., Mierzejewski M., Debniak T., Teodorczyk U., Byrski T., Gronwald J., Matyjasik J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004 Oct 18;75(6):1131–1135. doi: 10.1086/426403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Debniak Tadeusz, Górski Bohdan, Scott Rodney J., Cybulski Cezary, Medrek Krzysztof, Zowocka Elzbieta, Kurzawski Grzegorz, Debniak Boguslaw, Kadny Józef, Bielecka-Grzela Stanislawa. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer. 2004 Jul 1;110(4):558–562. doi: 10.1002/ijc.20163. [DOI] [PubMed] [Google Scholar]
- Debniak Tadeusz, Scott Rodney J., Huzarski Tomasz, Byrski Tomasz, Rozmiarek Andrzej, Debniak Bogusław, Załuga Elzbieta, Maleszka Romuald, Kładny Józef, Górski Bohdan. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res. 2005 Feb 1;65(3):835–839. [PubMed] [Google Scholar]
- Ghiorzo P., Ciotti P., Mantelli M., Heouaine A., Queirolo P., Rainero M. L., Ferrari C., Santi P. L., De Marchi R., Farris A. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer. 1999 Nov 12;83(4):441–448. doi: 10.1002/(sici)1097-0215(19991112)83:4<441::aid-ijc2>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
- Gorgoulis V. G., Koutroumbi E. N., Kotsinas A., Zacharatos P., Markopoulos C., Giannikos L., Kyriakou V., Voulgaris Z., Gogas I., Kittas C. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med. 1998 Dec;4(12):807–822. [PMC free article] [PubMed] [Google Scholar]
- Lamperska Katarzyna, Karezewska Aldona, Kwiatkowska Eliza, Mackiewicz Andrzej. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol. 2002;49(2):369–376. [PubMed] [Google Scholar]
- Lilischkis R., Sarcevic B., Kennedy C., Warlters A., Sutherland R. L. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer. 1996 Apr 10;66(2):249–254. doi: 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
- Monzon J., Liu L., Brill H., Goldstein A. M., Tucker M. A., From L., McLaughlin J., Hogg D., Lassam N. J. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998 Mar 26;338(13):879–887. doi: 10.1056/NEJM199803263381305. [DOI] [PubMed] [Google Scholar]
- Nichols K. E., Malkin D., Garber J. E., Fraumeni J. F., Jr, Li F. P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83–87. [PubMed] [Google Scholar]
- Nielsen N. H., Roos G., Emdin S. O., Landberg G. Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer. Cancer Lett. 2001 Feb 10;163(1):59–69. doi: 10.1016/s0304-3835(00)00674-1. [DOI] [PubMed] [Google Scholar]
- Prowse A. H., Schultz D. C., Guo S., Vanderveer L., Dangel J., Bove B., Cairns P., Daly M., Godwin A. K. Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet. 2003 Aug;40(8):e102–e102. doi: 10.1136/jmg.40.8.e102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ranade K., Hussussian C. J., Sikorski R. S., Varmus H. E., Goldstein A. M., Tucker M. A., Serrano M., Hannon G. J., Beach D., Dracopoli N. C. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995 May;10(1):114–116. doi: 10.1038/ng0595-114. [DOI] [PubMed] [Google Scholar]
- Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998 Oct 14;1378(2):F115–F177. doi: 10.1016/s0304-419x(98)00017-1. [DOI] [PubMed] [Google Scholar]
- Schneider-Stock Regine, Giers Anja, Motsch Christiane, Boltze Carsten, Evert Matthias, Freigang Bernd, Roessner Albert. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet. 2003 Jan;72(1):216–218. doi: 10.1086/345397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704–707. doi: 10.1038/366704a0. [DOI] [PubMed] [Google Scholar]
- Smigiel Robert, Sasiadek Maria, Krecicki Tomasz, Ramsey David, Jagielski Jozef, Blin Nikolaus. Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene in squamous cell carcinoma of the larynx. Mol Carcinog. 2004 Mar;39(3):147–154. doi: 10.1002/mc.20007. [DOI] [PubMed] [Google Scholar]
- Takahira Tomonari, Oda Yoshinao, Tamiya Sadafumi, Yamamoto Hidetaka, Kawaguchi Kenichi, Kobayashi Chikashi, Iwamoto Yukihide, Tsuneyoshi Masazumi. Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. Cancer Sci. 2004 Aug;95(8):651–655. doi: 10.1111/j.1349-7006.2004.tb03324.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Van Zee K. J., Calvano J. E., Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene. 1998 May 28;16(21):2723–2727. doi: 10.1038/sj.onc.1201794. [DOI] [PubMed] [Google Scholar]
- Whelan A. J., Bartsch D., Goodfellow P. J. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995 Oct 12;333(15):975–977. doi: 10.1056/NEJM199510123331505. [DOI] [PubMed] [Google Scholar]